Navigation Links
Exosome Diagnostics and QIAGEN Expand Collaboration to Develop Non-Invasive Biofluid Diagnostic for Lung Cancer
Date:1/13/2014

NEW YORK, Jan. 13, 2014 /PRNewswire/ -- Exosome Diagnostics today announced an expansion of its strategic collaboration with QIAGEN to develop non-invasive molecular diagnostics for use in detecting and monitoring actionable genetic mutations in lung cancer patients. In contrast with current molecular diagnostics requiring tissue biopsy, the focus will be to enable detection of well-understood cancer biomarkers in plasma, reducing both cost and patient risk.  Financial terms of the collaboration were not disclosed.

The program will focus on detection of known mutations associated with non-small cell lung cancer (NSCLC) and other malignancies that have the potential to be paired with targeted therapies. QIAGEN plans to submit the first diagnostic test developed under the collaboration to the Food and Drug Administration following clinical validation.

"The ability to perform molecular testing in blood represents an important advance in personalized medicine," said James McCullough, Chief Executive Officer of Exosome Diagnostics. "QIAGEN is the ideal partner to bring robust, regulated exosome technology products to the global clinical market place."   

Exosome Diagnostics' proprietary technology is focused on rapid, robust isolation of clinically actionable genetic biomarkers from blood, urine and cerebrospinal fluid for diagnosis, monitoring and companion diagnostic applications. The Company's clinical in vitro diagnostic products are designed to operate on widely available sequencing and PCR instruments. Exosome Diagnostics intends to launch the first in a series of blood-based mutation diagnostics in its CLIA laboratory beginning in 2014. 

Exosomes are the messenger packages in a fundamental biological communication system that transmits genetic instructions from cell to cell. The unique technology developed by Exosome Diagnostics allows non-invasive detection of key disease associated gene mutations and gene expressions in blood, urine and cerebrospinal fluid without the need for a surgical tissue biopsy.

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes and other microvesicles are packaged and shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, disease-specific nucleic acids. The company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The company is commercializing in vitro diagnostic tests for use in personalized medicine and real-time monitoring of disease. For more information, please visit www.exosomedx.com.

 


'/>"/>
SOURCE Exosome Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cedars-Sinai Medical Center to Use Exosome Diagnostics Exosome RNA Biofluid Kits in Neo-Natal Setting and Cancer for Development of Personalized Medicine Diagnostics
2. QIAGEN Partners with Exosome Diagnostics to Create High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research
3. Exosome Diagnostics Names Kapil Dhingra Chairman of the Board of Directors
4. ResearchMoz.us: MicroRNAs and Exosomes Market Report 2012 - Industry Research Report
5. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
6. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
7. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
8. UC San Francisco and Quest Diagnostics Launch Collaboration to Advance the Field of Precision Medicine
9. Life Technologies to Provide Ion Torrent Sequencing Platform to Quest Diagnostics for Development of New Molecular Tests
10. Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics
11. Molecular Diagnostics Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... proud to announce it has become the premiere team-building cooking event company in San Diego. ... such as Illumina, HP and Qualcomm, and is ranked #1 in its category on Trip ... its new team building format, a way for teams to not only interact with one ...
(Date:3/23/2017)... MILFORD, Mass. , March 23, 2017 ... leading partner to global in vitro diagnostics ... launch of the industry,s first multiplexed ... inherited disease testing by next-generation sequencing ... materials were developed with input from industry ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... by the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. ... Women of Innovation Awards Dinner. , The dinner recognizes women accomplished in science, ...
(Date:3/23/2017)... ALBANY, New York , March 23, 2017 ... animal blood plasma products and derivatives market is fragmented due to the ... large players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, ... clear leader, these three companies, collectively, held more than 76% of ... ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
Breaking Biology News(10 mins):